Coexistence of Fabry's disease and systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 16, Issue 4, 1998, Pages 475-478

  Rahman, P ^a   Gladman, D D ^a,c   Wither, J ^b   Silver, M D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Apoptosis; Ceramide; Fabry's disease; SLE

Indexed keywords

ALPHA GALACTOSIDASE; ANTINUCLEAR ANTIBODY; CERAMIDE; DOUBLE STRANDED DNA; LYSOSOME ENZYME; SPHINGOMYELIN;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DYSPNEA; FABRY DISEASE; FEMALE; HEART TRANSPLANTATION; HUMAN; KERATOPATHY; MOUTH ULCER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA;

ALPHA-GALACTOSIDASE; ENDOCARDIUM; FABRY DISEASE; FEMALE; GLYCOSPHINGOLIPIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYSOSOMES; MIDDLE AGED; MYOCARDIUM;

EID: 0031825467     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BRADY RO, GAL AE, BRADLEY RM, MARTENSSON E, WARSHAW AL, LASTER L: Enzymatic defect in Fabry's disease. Cereidetrihexosidase deficiency. N Engl J Med 1967: 276: 1163-7.
2. DESNICK RJ, IOANNOU YA, ENG CM: Alphagalactosidase A deficiency: Fabry disease. In SCRIVER CR, BEAUDET AL, SLY WS, VALLE D (Eds.): The Molecular Basis of Inherited Disease, 6th ed., New York, McGraw-Hill, pp. 2741-84.
3. BURDA CD, WINDER PR: Angiokeratoma corporis diffusum univarsale (Fabry's disease) in female subjects. Am J Med 1967; 42: 293-301.
4. BROADMENT JC, EDWARDS WD, GORDIN H, HARTZLER GO, KRAWISZ JE: Fabry cardiomuapathy in the female confirmed by endometrial biopsy. Mayo Clin Proc 1981; 56: 623-8.
5. VON SCHEIDT W, ENG CM, FITZMAURICE TF et al.: An atypical variant of Fabry's disease disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-9.
6. HILLSLEY RE, HERNANDEZ E, STEENBERGEN C, BASHORE TM, HARRISON JK: Inherited restricted cardiomyopathy in a 74-year-old woman: A case of Fabry's disease. Am Heart J 1995; 129: 199-202.
7. LOEB H, JONNIAUX G, TONDEUR M et al.: Etude clinique, biochimique et ultrastructurelle de la maladie de Fabry chez l'enfant. Helv Paediat Acta 1968; 3: 269-86.
8. ROSENMANN E, KOBRIN I, COHEN T: Kidney involvement in SLE and Fabry's disease. Nephron 1983; 34: 180-4.
9. MAJIMA K, ISHIZAKI T, INOUE T et al.: A case of Fabry's disease associated with lupus nephritis.Nippon Jinzo Gakkai Shi 1992; 34: 1189-94.
10. DESNICK RJ, DOUGHMAN DJ, RILEY FC, WHITELY CG: Fabry keratopathy: Molecular pathology of chloroquine induced phenocopy. Am J Hum Genet 1974; 26; A26.
11. FESSEL WJ: Systemic lupus erythematosus in the community: Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974; 134: 1027-35.
12. HAMERS NM, DONKER-KOOPMAN WE, COULON-MORELAC MJ, DUPOUEY P, TRAGER JM: Characterization of antibodies against ceramide trihexoside and globoside. Immunocytochemistry 1978: 35: 353-8.
13. MCALARNEY T, OGINO M, APOPTOLSKI S, LATOV N: Specificity and cross reactivity of anti-galactocerebroside antibodies. Immunol Invest 1995; 24: 595-606.
14. SHOENFELD Y, BERESOVSKI A, ZHARHARY D et al.: Natural autoantibodies in sera of patients with Gaucher's disease. J Clin Immunol 1995; 15:6:363-372.
15. POZIN D, MENEGUS AM, KIRSCHNER G et al.: Effects of gangliosides on the expression of autoimmune demyelination in the peripheral nervous system. Ann Neurol 1991; 30: 678-85.
16. KASAI N, PACHNER AR, YU RK: Antiglycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 1986; 75: 33-42.
17. ENDO T, SCOTT DD, STEWART SS, KUNDU SK, MARCUS DM: Antibodies to glycosphigolipids in patients with multiple sclerosis and SLE. J Immunol 1984; 133: 1793-7.
18. COSTALLATT LT, DE OLIVEIRA RM, SANTIAGO MB, COSSERMELLI W, SAMARA AM: Neuropsychiatrie manifestations of systemic lupus erythematosus: The value of anticardiolipin, antigangliosides and antigalactocerebrocides antibodies. Clin Rheumatol 1990; 4: 489-97.
19. SHOENFELD Y, BERESOVSKI A, ZHARHARY D et al.: Natural autoantibodies in sera of patients with Gaucher's disease. J Clin Immunol 1995; 15: 363-72.
20. OBEID LM, HANNUN YA. Ceramide: A stress signal and mediator of growth suppression and apoptosis. J Cellular Biochem 1995; 58: 191-8.
21. HANNUN YA: Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274: 1855-9.
22. OLSHEFSKI R, TAYLOR B, HETTGER A, HASEGAWA A, LADISCH S: Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes. Eur J Biochem 1996; 241: 47-55.
23. JARVIS WD, KOLESNICK RN, FORANARI FA et al.: Induction of apoptotoic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci 1994; 91: 73-7.
24. NAGATA S, SUDA T: Fas and fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39-43.
25. ROUQET N, CARLIER K, BRIAND P, WIELS J, JOULIN V: Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Biochem Biophys Res Commun 1996; 229: 27-35.